HRP20140098T1 - Derivati piridin-4-ila kao agonisti s1p1/edg1 - Google Patents

Derivati piridin-4-ila kao agonisti s1p1/edg1 Download PDF

Info

Publication number
HRP20140098T1
HRP20140098T1 HRP20140098AT HRP20140098T HRP20140098T1 HR P20140098 T1 HRP20140098 T1 HR P20140098T1 HR P20140098A T HRP20140098A T HR P20140098AT HR P20140098 T HRP20140098 T HR P20140098T HR P20140098 T1 HRP20140098 T1 HR P20140098T1
Authority
HR
Croatia
Prior art keywords
methyl
pyridin
oxadiazol
methoxy
ethyl
Prior art date
Application number
HRP20140098AT
Other languages
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Keith Morrison
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140098(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of HRP20140098T1 publication Critical patent/HRP20140098T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (29)

1. Spoj, naznačen time, da ima formulu (I), [image] u kojoj A predstavlja [image] gdje zvjezdice označuju vezu koja je spojena na piridinsku skupinu formule (I); R1 predstavlja 3-pentil, 3-metil-but-1-il, ciklopentil, ili cikloheksil; R2 predstavlja metoksi; R3 predstavlja 2,3-dihidroksipropoksi, -OCH2-CH(OH)-CH2-NHCO-CH2OH, -OCH2-CH(OH)-CH2N(CH3)-COCH2OH, -NHSO2CH3, ili -NHSO2CH2CH3; i R4 predstavlja etil ili kloro; ili njegove soli.
2. Spoj prema zahtjevu 1, naznačen time, da je stereocentar u S-konfiguraciji od R3 skupina 2,3-dihidroksipropoksi, -OCH2-CH (OH)-CH2-NHCO-CH2OH, i -OCH2-CH(OH)-CH2N(CH3)-CO-CH2OH, ili njegove soli.
3. Spoj prema zahtjevu 1, naznačen time, da je stereocentar u R-konfiguraciji od R3 skupina 2,3-dihidroksipropoksi, -OCH2-CH (OH)-CH2-NHCO-CH2OH, i -OCH2-CH(OH)-CH2N(CH3)-CO-CH2OH, ili njegove soli.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da A predstavlja [image] gdje zvjezdice označuju vezu koja je spojena na piridinsku skupinu formule (I); ili njegove soli.
5. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da A predstavlja [image] gdje zvjezdice označuju vezu koja je spojena na piridinsku skupinu formule (I); ili njegove soli.
6. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da A predstavlja [image] ili njegove soli.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R1 predstavlja 3-pentil, ili njegove soli.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R1 predstavlja 3-metil-but-1-il, ili njegove soli.
9. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R1 predstavlja ciklopentil, ili njegove soli.
10. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R1 predstavlja cikloheksil, ili njegove soli.
11. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da R3 predstavlja 2,3-dihidroksipropoksi, ili njegove soli.
12. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da R3 predstavlja -OCH2-CH(OH)-CH2-NHCO-CH2OH, ili njegove soli.
13. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da R3 predstavlja -OCH2-CH(OH)-CH2N(CH3)-CO-CH2OH, ili njegove soli.
14. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da R3 predstavlja -NHSO2CH3, ili njegove soli.
15. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da R3 predstavlja -NHSO2CH2CH3, ili njegove soli.
16. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da R4 predstavlja etil, ili njegove soli.
17. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da R4 predstavlja klor, ili njegove soli.
18. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: (S)-3-(2-etil-4-{5-[2-(1-etil-propil)-6-metoksi-piridin-4-il]-[1,2,4]oksadiazol-3-il}-6-metil-fenoksi)-propan-1,2-diol; (S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; (R)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; (S)-3-{4-[5-(2-cikloheksil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; etansulfonska kiselina-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenil}-amid; N-[(S)-3-(2-etil-4-{5-[2-(1-etil-propil)-6-metoksi-piridin-4-il]-[1,2,4]oksadiazol-3-il}-6-metil-fenoksi)-2-hidroksi-propil]-2-hidroksi-acetamid; N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; N-((S)-3-{4-[5-(2-cikloheksil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-N-metil-acetamid; N-(2-kloro-4-{5-[2-(1-etil-propil)-6-metoksi-piridin-4-il]-[1,2,4]oksadiazol-3-il}-6-metil-fenil)-metansulfonamid; N-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenil}-metansulfonamid; (S)-3-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenoksi}-propan-1,2-diol; N-((S)-3-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; (S)-3-(2-etil-4-{5-[2-metoksi-6-(3-metil-butil)-piridin-4-il]-[1,2,4]oksadiazol-3-il}-6-metil-fenoksi)-propan-1,2-diol; N-[(S)-3-(2-etil-4-{5-[2-metoksi-6-(3-metil-butil)-piridin-4-il]-[12,4]oksadiazol-3-il}-6-metil-fenoksi)-2-hidroksi-propil]-2-hidroksi-acetamid; N-{2-kloro-4-[5-(2-cikloheksil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenil}-metansulfonamid; N-(2-etil-4-{5-[2-(1-etil-propil)-6-metoksi-piridin-4-il]-[1,2,4]oksadiazol-3-il}-6-metil-fenil)-metansulfonamid; N-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenil}-metansulfonamid; N-{4-[5-(2-cikloheksil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenil}-metansulfonamid; (S)-3-{4-[3-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-5-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; (R)-3-{4-[3-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-5-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; N-((S)-3-{4-[3-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-5-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; N-((R)-3-{4-[3-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-5-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; (S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,3,4]oksadiazol-2-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; (R)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,3,4]oksadiazol-2-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol; N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,3,4]oksadiazol-2-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; i N-((R)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,3,4]oksadiazol-2-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-acetamid; ili soli tih spojeva.
19. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: (S)-3-{2-kloro-4-[5-(2-cikloheksil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil- fenoksi}-propan-1,2-diol; i N-(2-etil-4-(5-(2-izopentil-6-metoksipiridin-4-il)-1,2,4-oksadiazol-3-il)-6-metilfenil)metansulfonamid; ili soli tih spojeva.
20. Spoj prema zahtjevu 1, naznačen time, da je to (S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil- fenoksi}-propan-1,2-diol ili njegova sol.
21. Spoj prema zahtjevu 1, naznačen time, da je to N-((S)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-2-hidroksi-propil)-2-hidroksi-N-metil-acetamid ili njegova sol.
22. Spoj prema zahtjevu 1, naznačen time, da je to N-{2-kloro-4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-6-metil-fenil}-metansulfonamid ili njegova sol.
23. Spoj prema zahtjevu 1, naznačen time, da je to N-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenil}-metansulfonamid ili njegova sol.
24. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 23, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
25. Spoj prema bilo kojem od zahtjeva 1 do 23 ili njegova farmaceutski prihvatljiva sol ili farmaceutski sastav prema zahtjevu 24, naznačen(a) time, da se upotrebljava kao lijek.
26. Spoj prema bilo kojem od zahtjeva 1 do 23 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju bolesti ili poremećaja povezanih s aktiviranjem imunološkog sustava.
27. Spoj prema bilo kojem od zahtjeva 1 do 23 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju bolesti ili poremećaja odabranih iz skupine koju čine odbacivanje transplatiranih organa kao što su bubrezi, jetra, srce, pluća, gušterača, rožnica i koža; bolesti koje izaziva usadak protiv stanice domaćina nastale nakon transplatacije matičnih stanica; autoimuni sindromi uključujući reumatoidni artritis, multiplu sklerozu, upalne bolesti crijeva kao što su Crohnova bolest i ulcerativni kolitis, psorijazu, psorijastični artritis, tiroiditis kao što je Hashimotoov tiroiditis, uveo-retinitis; atopijske bolesti kao što su rinitis, konjunktivitis, dermatitis; astma; dijabetes tipa I; autoimune bolesti nastale nakon infekcija uključujući reumatsku groznicu i postinfekcijski glomerulonefritis; čvrsti tumori i metastaze tumora.
28. Spoj prema bilo kojem od zahtjeva 1 do 23 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju bolesti ili poremećaja odabranih iz skupine koju čine odbacivanje transplantiranih organa kao što su bubrezi, jetra, srce i pluća; bolesti koje izaziva usadak protiv stanice domaćina nastale nakon transplantacije matičnih stanica; autoimuni sindromi uključujući reumatoidni artritis, multiplu sklerozu, psorijazu, psorijatički artritis, Crohnovu bolest i Hashimotoov tiroiditis; te atopijski dermatitis.
29. Spoj prema bilo kojem od zahtjeva 1 do 23 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju multiple skleroze ili psorijaze.
HRP20140098AT 2009-07-16 2014-02-04 Derivati piridin-4-ila kao agonisti s1p1/edg1 HRP20140098T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009053089 2009-07-16
PCT/IB2010/053224 WO2011007324A1 (en) 2009-07-16 2010-07-15 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
HRP20140098T1 true HRP20140098T1 (hr) 2014-03-14

Family

ID=42734812

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140098AT HRP20140098T1 (hr) 2009-07-16 2014-02-04 Derivati piridin-4-ila kao agonisti s1p1/edg1

Country Status (27)

Country Link
US (1) US8658675B2 (hr)
EP (1) EP2454255B1 (hr)
JP (1) JP5036923B1 (hr)
KR (1) KR101409131B1 (hr)
CN (1) CN102471328B (hr)
AR (1) AR077413A1 (hr)
AU (1) AU2010272219B2 (hr)
BR (1) BR112012000763B8 (hr)
CA (1) CA2767585C (hr)
CY (1) CY1114759T1 (hr)
DK (1) DK2454255T3 (hr)
ES (1) ES2441845T3 (hr)
HK (1) HK1170479A1 (hr)
HR (1) HRP20140098T1 (hr)
IL (1) IL217490A (hr)
MA (1) MA33528B1 (hr)
MX (1) MX2012000414A (hr)
MY (1) MY153617A (hr)
NZ (1) NZ598173A (hr)
PL (1) PL2454255T3 (hr)
PT (1) PT2454255E (hr)
RU (1) RU2547098C2 (hr)
SG (1) SG178042A1 (hr)
SI (1) SI2454255T1 (hr)
TW (1) TWI410421B (hr)
WO (1) WO2011007324A1 (hr)
ZA (1) ZA201201125B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002593A1 (es) * 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
NZ580454A (en) * 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
ATE502938T1 (de) * 2007-08-17 2011-04-15 Actelion Pharmaceuticals Ltd Pyridinderivate als s1p1/edg1-rezeptormodulatoren
JP5517944B2 (ja) * 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
ES2389042T3 (es) * 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
ES2389469T3 (es) * 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
NZ588438A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
AR084883A1 (es) * 2011-01-19 2013-07-10 Actelion Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo
CA2873439A1 (en) * 2012-05-22 2013-11-28 Actelion Pharmaceuticals Ltd New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
SI2970236T1 (sl) 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivati piridil-4-ila
CN107667104B (zh) * 2015-05-20 2022-03-22 爱杜西亚药品有限公司 (s)-3-{4-[5-(2-环戊基-6-甲氧基-吡啶-4-基)-[1,2,4]噁二唑-3-基]-2-乙基-6-甲基-苯氧基}-丙烷-1,2-二醇的结晶形式
EP3590929B1 (en) * 2017-02-28 2021-09-15 Medshine Discovery Inc. Spiro compound and use thereof
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法
CN107445941A (zh) * 2017-08-14 2017-12-08 河南科技大学第附属医院 具有免疫抑制活性的三氮唑类化合物的制备方法及应用
CN107311994A (zh) * 2017-08-14 2017-11-03 淄博职业学院 一种s1p‑1受体激动剂药物分子的新型合成方法
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021148314A1 (en) 2020-01-20 2021-07-29 Idorsia Pharmaceuticals Ltd Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US20230055568A1 (en) 2020-02-06 2023-02-23 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome
EP4116294A1 (en) * 2020-03-04 2023-01-11 Helioeast Pharmaceutical Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
JP2024510647A (ja) * 2021-04-09 2024-03-08 ヒーリオイースト ファーマシューティカル カンパニー リミテッド オキサジアゾール置換スピロ環系化合物とその使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2024056631A1 (en) 2022-09-14 2024-03-21 Idorsia Pharmaceuticals Ltd S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
CA2051494C (en) 1990-09-20 2006-03-14 Robert J. Dinerstein 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
ES2292830T3 (es) 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
RU2331639C2 (ru) * 2002-08-23 2008-08-20 Райджел Фармасьютикалз, Инк. Пиридилзамещенные гетероциклы, пригодные для лечения или профилактики инфекции, вызванной вирусом гепатита с
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2524867A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
EP1670463A2 (en) 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en) * 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
US8022063B2 (en) 2004-05-29 2011-09-20 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
WO2006064757A1 (ja) 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
JP5072825B2 (ja) 2005-03-23 2012-11-14 アクテリオン ファーマシューティカルズ リミテッド スフィンゴシン−１−ホスフェート−１受容体アゴニストとしての新規チオフェン誘導体
NZ562562A (en) 2005-03-23 2010-11-26 Actelion Pharmaceuticals Ltd Hydrogenated benzo(C)thiophene derivatives as immunomodulators
BRPI0609665A2 (pt) 2005-03-23 2010-04-20 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
EP1874772A1 (en) 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
MX2007013263A (es) 2005-04-26 2008-01-22 Neurosearch As Novedosos derivados oxadiazol y su uso medico.
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
US20070043104A1 (en) 2005-06-10 2007-02-22 Luthman Ingrid K UII-modulating compounds and their use
JP2008546758A (ja) 2005-06-24 2008-12-25 アクテリオン ファーマシューティカルズ リミテッド 新規チオフェン誘導体
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2007098474A1 (en) 2006-02-21 2007-08-30 University Of Virginia Patent Foundation Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
RS20080525A (en) 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
CL2007002593A1 (es) * 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
KR101454937B1 (ko) 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
RU2442780C2 (ru) 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
BRPI0717656A2 (pt) 2006-09-29 2014-04-29 Novartis Ag Derivados de diaril oxadiazol
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
NZ580454A (en) * 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
ATE502938T1 (de) 2007-08-17 2011-04-15 Actelion Pharmaceuticals Ltd Pyridinderivate als s1p1/edg1-rezeptormodulatoren
AU2008306886B2 (en) 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
JP5517944B2 (ja) * 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
AU2008326184A1 (en) 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
CA2706834A1 (en) 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of s1p1/edg1
CN101965346A (zh) 2008-03-06 2011-02-02 埃科特莱茵药品有限公司 新颖嘧啶-吡啶衍生物
ES2389042T3 (es) 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
NZ588438A (en) 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
ES2389469T3 (es) 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
MY172105A (en) 2008-05-14 2019-11-14 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
UY32734A (es) 2009-06-26 2010-11-30 Glaxo Group Ltd Compuestos agonistas del receptor esfingosina 1-fosfato

Also Published As

Publication number Publication date
CN102471328A (zh) 2012-05-23
CY1114759T1 (el) 2016-12-14
RU2012105134A (ru) 2013-08-27
SI2454255T1 (sl) 2014-01-31
MX2012000414A (es) 2012-02-08
RU2547098C2 (ru) 2015-04-10
US20120108638A1 (en) 2012-05-03
CN102471328B (zh) 2015-04-01
ES2441845T3 (es) 2014-02-06
JP5036923B1 (ja) 2012-09-26
TW201107313A (en) 2011-03-01
KR101409131B1 (ko) 2014-06-17
NZ598173A (en) 2014-01-31
EP2454255A1 (en) 2012-05-23
BR112012000763A2 (pt) 2018-03-13
AR077413A1 (es) 2011-08-24
ZA201201125B (en) 2014-07-30
DK2454255T3 (da) 2013-12-16
BR112012000763B1 (pt) 2021-02-09
WO2011007324A1 (en) 2011-01-20
AU2010272219B2 (en) 2015-02-26
CA2767585C (en) 2017-09-26
CA2767585A1 (en) 2011-01-20
JP2012533533A (ja) 2012-12-27
MA33528B1 (fr) 2012-08-01
US8658675B2 (en) 2014-02-25
MY153617A (en) 2015-02-27
TWI410421B (zh) 2013-10-01
KR20120069662A (ko) 2012-06-28
HK1170479A1 (en) 2013-03-01
AU2010272219A1 (en) 2012-03-08
EP2454255B1 (en) 2013-11-06
IL217490A (en) 2015-10-29
PL2454255T3 (pl) 2014-04-30
SG178042A1 (en) 2012-03-29
IL217490A0 (en) 2012-02-29
BR112012000763B8 (pt) 2021-05-25
PT2454255E (pt) 2014-01-14

Similar Documents

Publication Publication Date Title
HRP20140098T1 (hr) Derivati piridin-4-ila kao agonisti s1p1/edg1
HRP20130181T1 (hr) Derivati piridin-4-ila kao sredstva imunomodulacije
JP2009523165A5 (hr)
HRP20140335T1 (hr) Derivati amino-piridina kao agonisti s1p1/edg1-receptora
JP6853619B2 (ja) シアノトリアゾール化合物の医薬用途
HRP20120962T1 (hr) Derivati tiofena kao agonisti s1p1/edg1 receptora
HRP20171763T1 (hr) Derivati piridin-4-ila
KR101345473B1 (ko) 헤테로 화합물
JP5708936B2 (ja) 置換アミド化合物
US9260416B2 (en) Heterocyclic autotaxin inhibitors and uses thereof
JP2013536200A (ja) オートタキシン阻害剤およびその使用
JP5043105B2 (ja) 有機化合物
JP2014508111A (ja) リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
RU2733750C2 (ru) Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
JP5781611B2 (ja) Ｌｒｒｋ２キナーゼ阻害剤としての２−（ベンジルオキシ）ベンズアミド類
RU2019132212A (ru) Селективные ингибиторы hdac6
CA2667545A1 (en) Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
JP2013517264A5 (hr)
CN113396145A (zh) Pfkfb3抑制剂及其用途
KR20170094263A (ko) Ｎａｄｐｈ 옥시다제 억제제인 아미도 티아디아졸 유도체
RU2010140854A (ru) Пиридин-2-ильные производные в качестве иммуномодулирующих агентов
WO2013059928A1 (en) Hiv protease inhibitors
JP2011510029A5 (hr)
JP2014513122A5 (hr)
HRP20150919T1 (hr) Derivati 2-metoksi-piridin-4-ila